We are live on ! Find out more
AIM icon

AIM ImmunoTech
AIM

34 hedge funds and large institutions have $1.97M invested in AIM ImmunoTech in 2023 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 3

13% more funds holding

Funds holding: 30 → 34 (+4)

0.38% less ownership

Funds ownership: 9.27% → 8.89% (-0.38%)

33% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 6

56% less capital inflows, than outflows

Capital inflows: $81.7K | Capital outflows: $185K

Holders
34
Holders Change
+4
Holders Change %
+13.33%
% of All Funds
0.54%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
4
Reduced
6
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Two Sigma Securities
Two Sigma Securities
New York
+$31.1K
2
Virtu Financial
Virtu Financial
New York
+$17.9K
3
UBS Group
UBS Group
Switzerland
+$10.2K
4
Renaissance Technologies
Renaissance Technologies
New York
+$8.32K
5
HRT Financial
HRT Financial
New York
+$6.66K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$113K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$36.6K
3
Geode Capital Management
Geode Capital Management
Massachusetts
-$18.1K
4
DRW Securities
DRW Securities
Illinois
-$5.55K
5
Jane Street
Jane Street
New York
-$5.24K

AIM Hedge Fund Activity: Q3 2023 in Review

34 of the 6,316 institutional investors tracked by Wall St. Rank reported a position in AIM ImmunoTech (AIM) for Q3 2023, worth a combined $1.97M — down 35% from $3.01M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new AIM positions and 3 closed out — a net gain of 4 holders — while 4 added to existing stakes and 6 trimmed.

The largest buyer was Two Sigma Securities, adding an estimated $31.1K. The largest seller was Morgan Stanley, cutting an estimated $113K.

  • 34 institutional investors held AIM ImmunoTech (AIM) as of Q3 2023, up from 30 in Q2 2023.
  • Funds reported $1.97M of AIM ImmunoTech stock for Q3 2023, down 35% quarter-over-quarter.
  • 7 funds opened new AIM ImmunoTech positions in Q3 2023 and 3 closed out, a net change of +4 holders.
  • The largest AIM ImmunoTech buyer in Q3 2023 was Two Sigma Securities, an estimated $31.1K added.
  • The largest AIM ImmunoTech seller in Q3 2023 was Morgan Stanley, an estimated $113K sold.

Based on aggregated 13F filings for Q3 2023.